206
Views
2
CrossRef citations to date
0
Altmetric
Original Article

Immunophenotype and function define TCRγδ + T-ALL as a distinct subgroup from TCRαβ + T-ALL patients

, , &
Pages 108-117 | Received 30 Nov 2018, Accepted 23 Jul 2019, Published online: 08 Aug 2019
 

Abstract

We recently demonstrated TCRγδ + T-ALL as a distinct subgroup from TCRαβ + T-ALL at genomic level. TCRγδ + T-ALL subgroup possess significant survival advantage compared to TCRαβ + T-ALL. In the present study, functional level differences in these two subgroups of T-ALL were studied to understand the immune scenario contributing to survival benefit of TCRγδ + T-ALL subgroup. TCRγδ clonal T-ALL patients showed significantly high levels of γδ T cells compared to TCRαβ clonal T-ALL patients. TCRγδ + T-ALL patients expressed significantly high central memory and terminally differentiated (TemRA) Vδ1 and Vδ2 T cells. TCR γδ clonal leukemic blasts stimulated increased number of Vδ2 T cells from healthy lymphocytes. TCR γδ clonal leukemic blasts were able to form efficient immune synapse with effector γδ T cells. The differences in immunophenotype, cytotoxicity and immune synapse formations corroborate TCRγδ + T-ALL as a distinct subgroup from TCRαβ + T-ALL patients and explain the survival benefit of TCRγδ + T-ALL patients.

Disclosure statement

No potential conflict of interest was reported by the authors.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.